Literature DB >> 20707222

Comparison of hepatitis A seroprevalence in blood donors in South Tunisia between 2000 and 2007.

N Louati1, L Feki, H Rekik, H Feki, M Chaabouni, A Hammami, J Gargouri, H Karray-Hakim.   

Abstract

The aim of the study was to assess hepatitis A virus (HAV) seroprevalence in blood donors from South Tunisia in two periods 2000 and 2007. Serum samples collected from 376 blood donors in each period aged 18 to 30 years from different regions of South Tunisia were analysed for anti-HAV IgG. The global seroprevalence of HAV infection was 85.9% in 2007 as compared with 94.9% in 2000. The seroprevalence in the 18-20 years age group was 91.9% in 2000 vs 80.6% in 2007, and increased to 99% in 2000 and 92% in 2007 in the subjects over 26. Taking account of geographic area, the HAV seroprevalence in Sfax city decreased from 88.9% in 2000 to 62.7% in 2007 (p < 0.001), but it is still approximatively the same in rural areas (98.4% and 96%) and in the governorates of South Tunisia (97.6% and 99.2%). In conclusion, the number of adults in the city of Sfax which are not immunized against HAV is increasing. Thus, adolescents and young adults are at risk to develop symptomatic and potentially severe hepatitis A.

Entities:  

Mesh:

Year:  2009        PMID: 20707222

Source DB:  PubMed          Journal:  Arch Inst Pasteur Tunis        ISSN: 0020-2509


  2 in total

1.  Detection and Molecular Characterization of Hepatitis A Virus from Tunisian Wastewater Treatment Plants with Different Secondary Treatments.

Authors:  Imen Ouardani; Syrine Turki; Mahjoub Aouni; Jesús L Romalde
Journal:  Appl Environ Microbiol       Date:  2016-06-13       Impact factor: 4.792

2.  Migration pattern of hepatitis A virus genotype IA in North-Central Tunisia.

Authors:  Abir Beji-Hamza; Stefania Taffon; Salma Mhalla; Alessandra Lo Presti; Michele Equestre; Paola Chionne; Elisabetta Madonna; Eleonora Cella; Roberto Bruni; Massimo Ciccozzi; Mahjoub Aouni; Anna Rita Ciccaglione
Journal:  Virol J       Date:  2015-02-08       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.